Biguanides drugs: Past success stories and promising future for drug discovery
Affiliation
Université Côte d'Azur, CNRS, Institut de Chimie de Nice UMR 7272, 28 Avenue Valrose, 06108, Nice, France; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, SK10 4TG,Issue Date
2021
Metadata
Show full item recordAbstract
Biguanides have attracted much attention a century ago and showed resurgent interest in recent years after a long period of dormancy. They constitute an important class of therapeutic agents suitable for the treatment of a wide spectrum of diseases. Therapeutic indications of biguanides include antidiabetic, antimalarial, antiviral, antiplaque, and bactericidal applications. This review presents an extensive overview of the biological activity of biguanides and different mechanisms of action of currently marketed biguanide-containing drugs, as well as their pharmacological properties when applicable. We highlight the recent developments in research on biguanide compounds, with a primary focus on studies on metformin in the field of oncology. We aim to provide a critical overview of all main bioactive biguanide compounds and discuss future perspectives for the design of new drugs based on the biguanide fragment.Citation
Grytsai O, Myrgorodska I, Rocchi S, Ronco C, Benhida R. Biguanides drugs: Past success stories and promising future for drug discovery. European Journal of Medicinal Chemistry. 2021 Nov;224:113726.Journal
European Journal of Medicinal ChemistryDOI
10.1016/j.ejmech.2021.113726PubMed ID
34364161Additional Links
https://dx.doi.org/10.1016/j.ejmech.2021.113726Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejmech.2021.113726
Scopus Count
Collections
Related articles
- Biguanides: Species with versatile therapeutic applications.
- Authors: Kathuria D, Raul AD, Wanjari P, Bharatam PV
- Issue date: 2021 Jul 5
- Synthetic accesses to biguanide compounds.
- Authors: Grytsai O, Ronco C, Benhida R
- Issue date: 2021
- Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents.
- Authors: Sweeney D, Raymer ML, Lockwood TD
- Issue date: 2003 Aug 15
- Metformin and other biguanides in oncology: advancing the research agenda.
- Authors: Pollak M
- Issue date: 2010 Sep
- A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides.
- Authors: Thompson MD, Thompson HJ
- Issue date: 2012 Dec